Nasal Product Line

About Aquilon Pharmaceuticals

Aquilon Pharmaceuticals is a private, clinical-stage biotech leveraging its proprietary HP-Betadex excipient platform to revolutionize inhaled drug delivery. The company aims to enhance the pharmacology and lung deposition of drugs for respiratory diseases, with a pipeline progressing through clinical trials. With strong academic roots and recent €6 million refinancing, Aquilon is positioning for the commercial launch of its nasal product line while advancing its dry powder inhaler formulations.

Therapeutic Areas